SI1720836T1 - 6-substituirani 2,3,4,5-tetrahidro-1h-benzo (d)azepini kot agonisti 5-ht2c receptorja - Google Patents

6-substituirani 2,3,4,5-tetrahidro-1h-benzo (d)azepini kot agonisti 5-ht2c receptorja

Info

Publication number: SI1720836T1
Authority: SI; Slovenia
Prior art keywords: šdćazepines; benzo; tetrahydro; substituted; receptor agonists
Prior art date: 2004-02-25

Application number

SI200531852T

Other languages

English (en)

Inventor

John Gordon Allen

Karin Briner

Michael Philip Cohen

Christopher Stanley Galka

Sarah Lynne Hellman

Maria Angeles Martinez-Grau

Matthew Robert Reinhard

Michael John Rodriguez

Roger Ryan Rothhaar

Michael Wade Tidwell

Frantz Victor

Andrew Caerwyn Williams

Deyi Zhang

Wai-Man Lee

Christopher Stephen Siedem

Ajay Singh

Original Assignee

Eli Lilly And Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-02-25

Filing date

2005-02-18

Publication date

2014-06-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34910927&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1720836(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-02-18 Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company

2014-06-30 Publication of SI1720836T1 publication Critical patent/SI1720836T1/sl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Hematology (AREA)
Obesity (AREA)
Anesthesiology (AREA)
Child & Adolescent Psychology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Addiction (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)

SI200531852T 2004-02-25 2005-02-18 6-substituirani 2,3,4,5-tetrahidro-1h-benzo (d)azepini kot agonisti 5-ht2c receptorja SI1720836T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US54768104P	2004-02-25	2004-02-25
PCT/US2005/005418 WO2005082859A1 (en)	2004-02-25	2005-02-18	6-substituted 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists
EP05723397.5A EP1720836B1 (en)	2004-02-25	2005-02-18	6-substituted 2,3,4,5-tetrahydro-1h-benzo [d]azepines as 5-ht2c receptor agonists

Publications (1)

Publication Number	Publication Date
SI1720836T1 true SI1720836T1 (sl)	2014-06-30

Family

ID=34910927

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI200531852T SI1720836T1 (sl)	2004-02-25	2005-02-18	6-substituirani 2,3,4,5-tetrahidro-1h-benzo (d)azepini kot agonisti 5-ht2c receptorja

Country Status (29)

Country	Link
US (2)	US8022062B2 (sl)
EP (2)	EP1720836B1 (sl)
JP (1)	JP4796047B2 (sl)
KR (1)	KR100848411B1 (sl)
CN (3)	CN1934088A (sl)
AR (1)	AR048242A1 (sl)
AU (1)	AU2005217602B2 (sl)
BR (1)	BRPI0507986A (sl)
CA (1)	CA2556390C (sl)
CL (1)	CL2010001292A1 (sl)
CR (1)	CR8566A (sl)
DK (1)	DK1720836T3 (sl)
DO (1)	DOP2005000024A (sl)
EA (1)	EA011011B1 (sl)
EC (1)	ECSP066788A (sl)
ES (2)	ES2466641T3 (sl)
IL (1)	IL177267A (sl)
MA (1)	MA28486B1 (sl)
MY (1)	MY141992A (sl)
NO (1)	NO20064277L (sl)
NZ (2)	NZ549009A (sl)
PE (1)	PE20060010A1 (sl)
PL (1)	PL1720836T3 (sl)
PT (1)	PT1720836E (sl)
SI (1)	SI1720836T1 (sl)
SV (1)	SV2005002025A (sl)
UA (1)	UA85699C2 (sl)
WO (1)	WO2005082859A1 (sl)
ZA (1)	ZA200606580B (sl)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1632494A1 (en)	2004-08-24	2006-03-08	Ferring B.V.	Vasopressin v1a antagonists
CA2619450C (en) *	2005-09-01	2013-10-22	Eli Lilly And Company	6-n-linked heterocycle-substituted 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists
SI1924560T1 (sl)	2005-09-01	2010-01-29	Lilly Co Eli	6-substituirani-2,3,4,5-tetrahidro-1h-benzo(d)azepini kot agonisti 5-ht2c receptorja
PT1924561E (pt) *	2005-09-01	2013-01-16	Lilly Co Eli	Módulo de cabeça de impressão tendo uma fiada solta e controlador de impressora para lhe fornecer dados
DK1926712T3 (da) *	2005-09-01	2009-11-09	Lilly Co Eli	6-Substituerede 2,3,4,5-tetrahydro-1H-benzo[D]azepiner som 5-HT2C-receptoragonister
WO2007132841A1 (ja)	2006-05-16	2007-11-22	Takeda Pharmaceutical Company Limited	縮合複素環化合物およびその用途
WO2007140213A1 (en)	2006-05-26	2007-12-06	Forest Laboratories Holdings Limited	Pyridoazepine derivatives
CA2666193A1 (en)	2006-08-08	2008-02-14	Sanofi-Aventis	Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use
WO2009063992A1 (ja)	2007-11-15	2009-05-22	Takeda Pharmaceutical Company Limited	縮合ピリジン誘導体およびその用途
WO2009111004A1 (en)	2008-03-04	2009-09-11	Arena Pharmaceuticals, Inc.	Processes for the preparation of intermediates related to the 5-ht2c agonist (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine
US8470841B2 (en)	2008-07-09	2013-06-25	Sanofi	Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
CN101712675B (zh) *	2008-10-07	2013-07-03	江苏恒谊药业有限公司	苯并含氮杂环衍生物及其在治疗神经精神疾病药物的应用
EP2362765B1 (en) *	2008-12-01	2020-04-08	The Procter and Gamble Company	Perfume systems
WO2010068601A1 (en)	2008-12-08	2010-06-17	Sanofi-Aventis	A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2011012622A1 (en)	2009-07-30	2011-02-03	Glaxo Group Limited	Benzoxazinone derivatives for the treatment of glytl mediated disorders
ES2443016T3 (es)	2009-08-26	2014-02-17	Sanofi	Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo
WO2011061318A1 (en)	2009-11-23	2011-05-26	N.V. Organon	Heterocylic compounds as antagonists of the orexin receptors
US20110269744A1 (en) *	2010-03-12	2011-11-03	Astellas Pharma Inc.	Benzazepine Compound
KR20130112848A (ko)	2010-06-02	2013-10-14	아레나 파마슈티칼스, 인크.	5-ｈｔ2ｃ 수용체 아고니스트의 제조 방법
AU2011296014A1 (en)	2010-09-01	2013-04-04	Arena Pharmaceuticals, Inc.	Salts of lorcaserin with optically active acids
SG188362A1 (en)	2010-09-01	2013-04-30	Arena Pharm Inc	Modified-release dosage forms of 5-ht2c agonists useful for weight management
EP2611449A1 (en)	2010-09-01	2013-07-10	Arena Pharmaceuticals, Inc.	Administration of lorcaserin to individuals with renal impairment
WO2012030951A1 (en) *	2010-09-01	2012-03-08	Arena Pharmaceuticals, Inc.	Fast-dissolve dosage forms of 5-ht2c agonists
WO2012030953A1 (en)	2010-09-01	2012-03-08	Arena Pharmaceuticals, Inc.	5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
KR20130101524A (ko) *	2010-09-01	2013-09-13	아레나 파마슈티칼스, 인크.	5-ｈｔ2ｃ 아고니스트의 비-흡습성 염
JP5809157B2 (ja)	2010-10-08	2015-11-10	持田製薬株式会社	環状アミド誘導体
EP2683698B1 (de)	2011-03-08	2017-10-04	Sanofi	Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120058A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683702B1 (de)	2011-03-08	2014-12-24	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828994B2 (en)	2011-03-08	2014-09-09	Sanofi	Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en)	2011-03-08	2014-10-28	Sanofi	Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120053A1 (de)	2011-03-08	2012-09-13	Sanofi	Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de)	2011-03-08	2012-09-13	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683703B1 (de)	2011-03-08	2015-05-27	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120052A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012147516A1 (ja)	2011-04-28	2012-11-01	持田製薬株式会社	環状アミド誘導体
EP2707373A1 (de)	2011-05-10	2014-03-19	Bayer Intellectual Property GmbH	Bicyclische (thio)carbonylamidine
CN103030604A (zh) *	2011-10-10	2013-04-10	上海医药工业研究院	4-烷基-5-甲酰基噻唑或5-甲酰基噻唑的制备方法
CN103145619A (zh) *	2012-06-15	2013-06-12	史慎德	7-氯-6-苯磺酰氨基-2,3,4,5-四氢-1H-苯并[d]氮杂*的制备
AU2012392187B2 (en)	2012-10-09	2018-07-12	Arena Pharmaceuticals, Inc.	Method of weight management
EP2919788A4 (en)	2012-11-14	2016-05-25	Univ Johns Hopkins	METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
EP2801575A1 (en)	2013-05-07	2014-11-12	Bayer CropScience AG	Heteroaryldihydropyridine derivatives as fungicides
WO2015066344A1 (en)	2013-11-01	2015-05-07	Arena Pharmaceuticals, Inc.	5-ht2c receptor agonists and compositions and methods of use
CN103864679B (zh) *	2014-03-21	2015-11-18	河南师范大学	一种3-甲基-2-吡啶甲酸甲酯的制备方法
CN104193656B (zh) *	2014-09-09	2016-01-06	太原理工大学	一种β-二羰基砜类化合物及其制备方法
CN105622511B (zh) *	2014-11-03	2018-01-23	北京瑞都医药科技有限公司	一种减肥药物及其制备方法
CN104496891A (zh) *	2014-12-06	2015-04-08	哈尔滨工业大学	吡啶衍生物2-叔丁氧基-6-亚甲基氯吡啶的合成方法
CA2982824C (en)	2015-04-30	2023-11-21	Musc Foundation For Research Development	Oxindole compounds and pharmaceutical compositions thereof
AU2016268096B2 (en)	2015-05-22	2021-04-01	Agenebio, Inc.	Extended release pharmaceutical compositions of levetiracetam
CN110621669A (zh)	2017-05-04	2019-12-27	巴斯夫欧洲公司	防除植物病原性真菌的取代5-卤代烷基-5-羟基异噁唑类
EP3733204A4 (en)	2017-12-27	2021-09-15	Takeda Pharmaceutical Company Limited	THERAPEUTIC FOR EXERCISE INCONTINENCE AND STAIR INCONTINENCE
MX2021009163A (es)	2019-02-01	2021-09-10	Fmc Corp	Piridinas y pirimidinas sustituidas con diamino como herbicidas.
JP2022534914A (ja)	2019-05-29	2022-08-04	シンジェンタクロッププロテクションアクチェンゲゼルシャフト	殺微生物性誘導体
EP4045498A4 (en) *	2019-10-14	2023-09-27	The Regents of the University of California	ANTICANCER COMPOUNDS WITH BROAD SPECTRUM ACTION
WO2021218863A1 (zh) *	2020-04-26	2021-11-04	江苏恩华药业股份有限公司	1,5-二氢-2,4-苯二氮䓬-3-酮衍生物及其应用
WO2024146945A1 (en)	2023-01-07	2024-07-11	Syngenta Crop Protection Ag	Novel carboxamide and sulfonamide pesticidal compounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2265890A (en) *	1939-11-25	1941-12-09	Arrow Hart & Hegeman Electric	Combined face plate and receptacle
ZA792785B (en) *	1978-07-07	1980-08-27	Smithkline Corp	Mercapto substituted-2,3,4,5-tetrahydro-1h-3-benzazepines
US4265890A (en)	1978-07-07	1981-05-05	Smithkline Corporation	6-Phenyl thio- and 6-cyclohexyl thio-2,3,4,5-tetrahydro-1H-3-benzazepines
US4349472A (en)	1979-04-27	1982-09-14	Schering Corporation	(S)-8(1-Adamantanecarbonyloxy)-7-chloro-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine
EP0285287A3 (en) *	1987-03-23	1990-08-16	Smithkline Beecham Corporation	3-benzazepine compounds for use in treating gastrointestinal motility disorders
US4985352A (en)	1988-02-29	1991-01-15	The Trustees Of Columbia University In The City Of New York	DNA encoding serotonin 1C (5HT1c) receptor, isolated 5HT1c receptor, mammalian cells expressing same and uses thereof
GB9116824D0 (en) *	1991-08-05	1991-09-18	Smithkline Beecham Corp	Chemical compounds
GB9119467D0 (en) *	1991-09-12	1991-10-23	Smithkline Beecham Corp	Chemical compounds
AU674613B2 (en)	1993-09-28	1997-01-02	Otsuka Pharmaceutical Co., Ltd.	Quinoxaline derivative as antidiabetic agent
US5698766A (en)	1995-04-05	1997-12-16	The Regents Of The University Of California	Transgenic animal model for testing drugs for treating eating disorders and epilepsy
WO2000069816A1 (en)	1999-05-17	2000-11-23	Eli Lilly And Company	Metabotropic glutamate receptor antagonists
WO2001007416A1 (de)	1999-07-28	2001-02-01	Lonza Ag	Verfahren zur herstellung von pyridazincarbonsäurederivaten
JP2003510322A (ja)	1999-09-29	2003-03-18	イーライ・リリー・アンド・カンパニー	再取り込みインヒビターとしてのピペリジン誘導体
GB0005789D0 (en)	2000-03-11	2000-05-03	Knoll Ag	Therapeutic agents
EP1213017A3 (en)	2000-12-05	2003-11-12	Akzo Nobel N.V.	Use of a 5-HT2C receptor agonist for the treatment of hot flushes
WO2002074746A1 (fr) *	2001-03-16	2002-09-26	Yamanouchi Pharmaceutical Co., Ltd.	Derives de benzazepine
DE60206762T2 (de)	2001-07-13	2006-07-13	Pharmacia & Upjohn Co. Llc, Kalamazoo	Hexahydroazepino(4,5-g)indole und -indoline als 5-ht rezeptor-liganden
BR0214529A (pt)	2001-11-28	2006-05-30	Upjohn Co	compostos terapêuticos
US6908939B2 (en)	2001-12-21	2005-06-21	Galderma Research & Development S.N.C.	Biaromatic ligand activators of PPARγ receptors
US6953787B2 (en)	2002-04-12	2005-10-11	Arena Pharmaceuticals, Inc.	5HT2C receptor modulators

2005
- 2005-02-18 SI SI200531852T patent/SI1720836T1/sl unknown
- 2005-02-18 NZ NZ549009A patent/NZ549009A/xx not_active IP Right Cessation
- 2005-02-18 CN CNA2005800057884A patent/CN1934088A/zh active Pending
- 2005-02-18 JP JP2007500906A patent/JP4796047B2/ja not_active Expired - Fee Related
- 2005-02-18 PL PL05723397T patent/PL1720836T3/pl unknown
- 2005-02-18 AU AU2005217602A patent/AU2005217602B2/en not_active Ceased
- 2005-02-18 EP EP05723397.5A patent/EP1720836B1/en active Active
- 2005-02-18 CN CN2011101820767A patent/CN102311387A/zh active Pending
- 2005-02-18 ES ES05723397.5T patent/ES2466641T3/es active Active
- 2005-02-18 KR KR1020067019634A patent/KR100848411B1/ko not_active IP Right Cessation
- 2005-02-18 US US10/598,302 patent/US8022062B2/en not_active Expired - Fee Related
- 2005-02-18 CA CA2556390A patent/CA2556390C/en not_active Expired - Fee Related
- 2005-02-18 BR BRPI0507986-1A patent/BRPI0507986A/pt not_active IP Right Cessation
- 2005-02-18 UA UAA200609265A patent/UA85699C2/ru unknown
- 2005-02-18 EP EP12161584.3A patent/EP2479168B1/en active Active
- 2005-02-18 NZ NZ586553A patent/NZ586553A/en not_active IP Right Cessation
- 2005-02-18 DK DK05723397.5T patent/DK1720836T3/da active
- 2005-02-18 EA EA200601546A patent/EA011011B1/ru not_active IP Right Cessation
- 2005-02-18 WO PCT/US2005/005418 patent/WO2005082859A1/en active Application Filing
- 2005-02-18 PT PT57233975T patent/PT1720836E/pt unknown
- 2005-02-18 CN CN2011101821562A patent/CN102329267A/zh active Pending
- 2005-02-18 ES ES12161584.3T patent/ES2468741T3/es active Active
- 2005-02-23 DO DO2005000024A patent/DOP2005000024A/es unknown
- 2005-02-24 PE PE2005000219A patent/PE20060010A1/es not_active Application Discontinuation
- 2005-02-24 MY MYPI20050730A patent/MY141992A/en unknown
- 2005-02-24 AR ARP050100686A patent/AR048242A1/es not_active Application Discontinuation
- 2005-02-25 SV SV2005002025A patent/SV2005002025A/es unknown
2006
- 2006-08-03 IL IL177267A patent/IL177267A/en not_active IP Right Cessation
- 2006-08-07 ZA ZA200606580A patent/ZA200606580B/xx unknown
- 2006-08-23 CR CR8566A patent/CR8566A/es unknown
- 2006-08-24 EC EC2006006788A patent/ECSP066788A/es unknown
- 2006-09-21 NO NO20064277A patent/NO20064277L/no not_active Application Discontinuation
- 2006-09-25 MA MA29343A patent/MA28486B1/fr unknown
2010
- 2010-11-25 CL CL2010001292A patent/CL2010001292A1/es unknown
2011
- 2011-07-28 US US13/192,707 patent/US8580780B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP2479168A1 (en)	2012-07-25
AR048242A1 (es)	2006-04-12
NO20064277L (no)	2006-11-22
AU2005217602A1 (en)	2005-09-09
KR100848411B1 (ko)	2008-07-28
CL2010001292A1 (es)	2011-07-15
EA011011B1 (ru)	2008-12-30
MA28486B1 (fr)	2007-03-01
JP2007523951A (ja)	2007-08-23
PL1720836T3 (pl)	2014-09-30
ES2466641T3 (es)	2014-06-10
DK1720836T3 (da)	2014-05-05
DOP2005000024A (es)	2005-11-15
BRPI0507986A (pt)	2007-07-24
UA85699C2 (en)	2009-02-25
IL177267A0 (en)	2006-12-10
PE20060010A1 (es)	2006-02-11
EA200601546A1 (ru)	2007-02-27
ZA200606580B (en)	2008-02-27
NZ549009A (en)	2010-08-27
EP1720836B1 (en)	2014-04-16
US20090099155A1 (en)	2009-04-16
PT1720836E (pt)	2014-07-16
SV2005002025A (es)	2005-11-04
JP4796047B2 (ja)	2011-10-19
KR20070001200A (ko)	2007-01-03
US20120028961A1 (en)	2012-02-02
US8580780B2 (en)	2013-11-12
AU2005217602B2 (en)	2011-02-17
US8022062B2 (en)	2011-09-20
CN102329267A (zh)	2012-01-25
IL177267A (en)	2011-10-31
MY141992A (en)	2010-08-16
CN102311387A (zh)	2012-01-11
CR8566A (es)	2006-12-01
CN1934088A (zh)	2007-03-21
ECSP066788A (es)	2006-11-16
ES2468741T3 (es)	2014-06-16
EP1720836A1 (en)	2006-11-15
WO2005082859A1 (en)	2005-09-09
CA2556390C (en)	2012-10-02
EP2479168B1 (en)	2014-04-09
NZ586553A (en)	2011-11-25
CA2556390A1 (en)	2005-09-09

Publication	Publication Date	Title
SI1720836T1 (sl)	2014-06-30	6-substituirani 2,3,4,5-tetrahidro-1h-benzo (d)azepini kot agonisti 5-ht2c receptorja
SI1924561T1 (sl)	2013-02-28	6-arilalkilamino-2,3,4,5-tetrahidro-1h-benzo(d)azepini kot agonisti 5-ht2c receptorja
SG156653A1 (en)	2009-11-26	2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin d2 receptor antagonists
EP1814550A4 (en)	2009-10-21	ANTAGONISTS OF N-SULFONYLPIPERIDINE CANNABINOID RECEPTOR 1
IL183706A0 (en)	2007-09-20	2,4(4,6) pyrimidine derivatives
IL177798A0 (en)	2006-12-31	Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
IL184233A0 (en)	2007-10-31	2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
IL188799A0 (en)	2008-08-07	Substituted tetrahydro-1h-pyrido[4,3,b]indoles as serotonin receptor agonists and antagonists
ZA200807380B (en)	2009-05-27	2,6-substituted-4-monosubstituted amino-pyrimidine as prostaglandin D2 receptor antagonists
EP1830858A4 (en)	2010-06-23	3,6-BICYCLOLIDE
IL174056A0 (en)	2006-08-01	Novel adenosine a3 receptor agonists
IL173337A0 (en)	2006-06-11	Receptor
GB0425572D0 (en)	2004-12-22	1,7-Naphthyridines
EP1636230A4 (en)	2010-06-16	ADENOSINE A1 RECEPTOR ANTAGONISTS
ZA200702193B (en)	2008-11-26	4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
AP2007003937A0 (en)	2007-04-30	4-Amino substituted-2-substituted-1,2,3,4-tetrahy droquinoline compounds
IL177721A0 (en)	2006-12-31	Adenosine receptor agonists
GB0321998D0 (en)	2003-10-22	Receptor
GB0408454D0 (en)	2004-05-19	Leptin receptor agonists (1)
GB0408398D0 (en)	2004-05-19	Leptin receptor agonists (3)
GB0307100D0 (en)	2003-04-30	Receptor
GB0329104D0 (en)	2004-01-21	Receptor
GB0404309D0 (en)	2004-03-31	Receptor